Court's ANDA Infringement Under Hatch-Waxman Determination
The US District Court for District of Delaware granted the plaintiff’s motion to exclude defendant’s expert testimony for being based on an erroneous legal theory in a suit alleging defendants’ generic ANDA product would infringe Exela’s patents under the Hatch-Waxman Act.
United States Sunovion Pharms Maryellen Noreika Teva Pharms Waxman Act Exela Pharma Sciences United States District Court
Source: natlawreview.com